Overview
Guardant Reveal
This is a clinical test intended for HelpPurposes or indications for the test. Lab-provided.: Monitoring, Recurrence, Therapeutic management
Loading data ......
Click Indication tab for more information.
Licensed physician contacts Guardant Health client services for ordering information.
Order URL HelpLink to the laboratory webpage with information about how to order this test. Please note that clicking on this link will open a new tab in your internet browser.: https://guardantreveal.com/
Specimen source
Peripheral (whole) blood
Plasma
- Molecular Genetics
- MMethylation analysis
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
- ESequence analysis of select exons
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
Summary of what is tested
Loading data ......
Click Methodology tab for more
information.
Guidance for management
A total of 252 prospective serial plasma specimens from 103 patients with colorectal cancer undergoing curative-intent surgery were analyzed and correlated with recurrence. Plasma-only MRD detection demonstrated favorable sensitivity and specificity for recurrence, comparable with tumor-informed approaches. Integrating analysis of epigenomic and genomic alterations enhanced sensitivity. These findings support the potential clinical utility of plasma-only ctDNA MRD detection.
Citations- Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, Kanter K, Fish MG, Fosbenner KD, Miao B, Phillips S, Carmichael JH, Sharma N, Jarnagin J, Baiev I, Shah YS, Fetter IJ, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Dubois JS, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, Nipp RD, Roeland EJ, Ryan DP, Weekes CD, Wo JY, Hong TS, Bordeianou L, Ferrone CR, Qadan M, Kunitake H, Berger D, Ricciardi R, Cusack JC, Raymond VM, Talasaz A, Boland GM, Corcoran RB. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021 Apr 29. doi: 10.1158/1078-0432.CCR-21-0410. Epub ahead of print. PMID: 33926918.
An approved physician with a Guardant Health account uses the Guardant sample collection kit to obtain a whole blood sample from the patient. Following Guardant shipping instructions, the sample is sent directly to the laboratory at Guardant Health. Turn around time for testing is 14 days. 000 Licensed physician contacts Guardant Health client services for ordering information.
- Liquid biopsy testing for somatic cancer gene variants
- Liquid biopsy testing for MRD